Clinical trials: Double Layer
Healthy
A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)
Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400 mg F.C.T (Al-debeiky pharma, Egypt)…
- Trial name
- NCT03062423
- Testing
- Sofodelevier, Sovaldi (fist dose), Sovaldi (second dose)
- Where
- Egypt
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Genuine Research Center, Egypt
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses
The primary objective of this trial was to investigate safety and tolerability of multiple doses of BI 409306 in healthy young and elderly volunteers.
- Trial name
- NCT01505894
- Testing
- BI 409306
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers
Study to demonstrate the bioequivalence of the telmisartan 80 mg film-coated tablet vs. two tablets of the telmisartan 40 mg conventional tablet
- Trial name
- NCT02261129
- Testing
- Telmisartan film-coated tablet, Telmisartan uncoated tablet
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions
The clinical investigation is an international, prospective, multi-center, double-blind, randomized safety and efficacy trial. The purpose of this study is to evaluate the safety and effectiveness of the TAXUS(TM)Stent System…
- Trial name
- TAXUS VI (NCT00297804)
- Testing
- TAXUS Express Paclitaxel-Eluting Coronary Stent System, Control stent
- Where
- Germany
- Volunteers
- 448 people
- Sponsor
- Boston Scientific Corporation
Angina (Stable), CAD - Coronary Artery Disease
Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease
The study objectives are: 1. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary ISR lesions 2.00-4.00 mm (inclusive) in diameter in patients with symptomatic coronary artery disease. 2.
- Conditions
- Angina (Stable), CAD - Coronary Artery Disease, Unstable Angina, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- ADVANCE-DUO (NCT07368933)
- Testing
- SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter
- Where
- 3 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Advanced NanoTherapies
Coxarthrosis; Primary
Ceramic Modular Dual Mobility in Primary Total Hip Arthroplasty (THA)
A randomized controlled trial comparing modular dual mobility inserts with ceramic multilayer coating versus standard polyethylene inserts for primary THA in a cementless acetabular cup
- Trial name
- CeMoD-prime (NCT05547984)
- Testing
- Dual Mobility Cup, Standard Acetabular component
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- Aesculap AG
Gastric Ulcer
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
Primary: To demonstrate that PA32540 causes fewer gastric ulcers in subjects at risk for developing aspirin-associated gastric ulcers compared to enteric coated (EC) aspirin 325 mg.
- Trial name
- NCT00960869
- Testing
- PA32540, EC-Aspirin 325 mg
- Where
- United States
- Volunteers
- 519 people
- Sponsor
- POZEN
Osteoarthritis
Hydroxyapatite (HA) Coating Versus Plasma Porous Spray (PPS) in Press-fit Acetabular Components Early Outcomes With DEXA
The study design comprises a randomized trial of patients undergoing primary total hip arthroplasty using the G7 acetabular system and Taperloc Complete stem comparing regular plasma porous spray with HA coating using Bonemaster…
- Trial name
- NCT02447653
- Testing
- G7 HA Acetabular Component, G7 PPS Acetabular Component
- Where
- Australia
- Volunteers
- 50 people
- Sponsor
- Zimmer Biomet
Renal Transplant
Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients
Purpose of study is to compare the efficacy of enteric-coated mycophenolate sodium compared to mycophenolate mofetil in Chinese patients (study conducted in China) as measured by the incidence of biopsy proven acute rejection…
- Trial name
- NCT00149903
- Testing
- Mycophenolate sodium (enteric coated)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions.
The main objective of this study is to assess the safety and effectiveness of the sirolimus-coated Bx VELOCITY™ stent in maintaining minimum lumen diameter in de novo native coronary artery lesions as compared to the uncoated Bx…
- Trial name
- E-SIRIUS (NCT00235144)
- Testing
- sirolimus-coated Bx Velocity stent, uncoated Bx Velocity stent
- Where
- 2 sites in Germany
- Volunteers
- 353 people
- Sponsor
- Cordis US Corp.
Acute Bronchitis
A Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of CANIUM Tab. in Acute Bronchitis Patients.
This study compared two oral medicines containing Pelargonium sidoides extract in patients aged 12 to 75 years with acute bronchitis.
- Trial name
- NCT07835620
- Testing
- DSP2505(Canium), Umckamin
- Where
- 12 sites in South Korea
- Volunteers
- 223 people
- Sponsor
- Dasan Pharmaceutical Co., Ltd.
Schizophrenia
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in schizophrenic patients following oral administration of multiple low, medium, and high doses over 14 days.
- Trial name
- NCT01892384
- Testing
- BI 409306
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim